Wei Wei | Liver Surgery | Sun Yat-sen University Cancer Center-Sun Yat-sen University Cancer Center

Name: Wei Wei

Title: Professor

Email: weiwei@sysucc.org.cn

Phone:

Profile

Dr. Wei Wei is associate professor of Department of Hepatobiliary Tumor of Sun Yat-sen University Cancer Center. Dr. Wei obtained his Bachelor in Medicine (equivalent to MD in the US) and PhD at Sun Yat-sen University of Medical Sciences, P. R. China in 2000 and 2008, respectively. From 2000, Dr.Wei was engage in the clinical and theoretical research of hepatobiliary tumor. In Apr 2008, Dr.Wei has participated the PATH project (Program For The Advancement of Therapy in Hepatocellular carcinoma) in Barcelona for a week. And he worked as visiting bachelor in Department of HPB and National Liver Transplantation Center of Austin Hospital of University of Melbourne from Mar 2009 to Sep 2009. Dr.Wei now is a main member of the research team in Department of Hepatobiliary Tumor and specialize in diagnosis and treatment of hepatobiliary tumor, including surgery, vascular intervention, local ablation and liver transplantation. The work of Dr.Wei and his team has got support by different fund including National natural science foundation of China and has published more than 10 SCI papers.

Interests

Diagnosis and treatment of hepatobiliary tumor, including surgery, vascular intervention, local ablation, target therapy and liver transplantation, especially the multidisciplinary treatments for advanced HCC.

Education

1995-2000 Faculty of clinical medicine of Sun Yat-sen University of Medical Sciences, Bachelor

2003-2005 Faculty of Clinical Oncology of Sun Yat-sen University, Master

2005-2008 Faculty of Clinical Oncology of Sun Yat-sen University, PhD

Publications

1. Chen ZY, Wei W, Guo ZX, Peng LX, Shi M, Li SH, Xiao CZ, Zhong C, Qian CN, Guo RP*. Using multiple cytokines to predict hepatocellular carcinoma recurrence in two patient cohorts. Br J Cancer. 2014 Feb 4;110(3):733-40.

2. Li SH, Wei W, Guo RP*, Shi M, Guo ZX, Chen ZY, Xiao CZ, Cai MY, Zheng L. Long-term outcomes after curative resection for patients with macroscopically solitary hepatocellular carcinoma without macrovascular invasion and an analysis of prognostic factors. Med Oncol. 2013 Dec;30(4):696.

3. Chen ZY, Shi M, Peng LX, Wei W, Li XJ, Guo ZX, Li SH, Zhong C, Qian CN, Guo RP. Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis. J Transl Med. 2012 Dec 10;10:245

4. Chen ZY, Wei W, Guo ZX, Lin JR, Shi M, Guo RP*. Morphologic classification of microvessels in hepatocellular carcinoma is associated with the prognosis after resection. J Gastroenterol Hepatol. 2011 May;26(5):866-74.

5. Luo HY, Wei W, Shi YX, Chen XQ, Li YH, Wang F, Qiu MZ, Li FH, Yan SL, Zeng MS, Huang P, Xu RH. Cetuximab enhances the effect of oxaliplatin on hypoxic gastric cancer cell lines. Oncol Rep. 2010 Jun;23(6):1735-45.

Updated by International Office, Sun Yat-sen University Cancer Center

Our Experts